Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Sponsor: Celgene
Listed as NCT01074047, this PHASE3 trial focuses on Acute Myeloid Leukemia and remains completed. Sponsored by Celgene, it has been updated 9 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
-
May 2017 — Sep 2017 [monthly]
Completed PHASE3
-
Feb 2017 — May 2017 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jun 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Alessandria, Italy , Amiens, France , Ancona, Italy , Angers, France , Aquitaine, France , Barcelona, Spain , Bari, Italy , Beer Yaakov, Israel , Beersheba, Israel and 89 more locations